Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study
- PMID: 27221874
- DOI: 10.7314/apjcp.2016.17.4.1903
Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study
Abstract
Background: Studies of effects of IL-1 polymorphisms, CYP2C19 genotype together with antibiotic resistance for H. pylori eradication are rare worldwide. The present study was designed to evaluate efficacy of 10-day sequential therapy (SQT) and 14-day standard triple therapy (STT) with four- times-daily dosing of amoxicillin for H. pylori eradication related to these important host and bacterial factors in Thailand.
Materials and methods: This prospective randomized study was performed during March 2015 to January 2016. H. pylori infected gastritis patients were randomized to receive 10-day sequential therapy and 14-day standard triple therapy. CYP2C19 genotyping, IL1 polymorphism (IL-1B and IL-1RN genotypes) and antibiotic susceptibility tests were performed in all patients. 13C-UBT was conducted to confirm H. pylori eradication at least 4 weeks after treatment.
Results: A total of 100 patients (33 males and 67 females, mean age=51.1 years) were enrolled. Eradication rate by PP analysis was 97.9% (47/48) with the 10-day SQT regimen and 87.8% (43/49) with 14-day STT regimen (97.9% vs 87.8%; p-value=0.053). Antibiotic susceptibility testing demonstrated 45% resistance to metronidazole, 14.8% to clarithromycin, and 24.1% to levofloxacin. CYP2C19 genotyping revealed 44.9% RM, 49% IM and 6.1% PM. IL-1B and IL-1RN genotypes were demonstrated as 21.4% for CC, 48.1% for TC, 36.8% for TT, 72.7% for 1/1, and 21.2% for 1/2 genotypes, respectively. The 10-day SQT regimen provided 100% eradication in patients with clarithromycin or dual clarithromycin and levofloxacin H. pylori resistant strains. Moreover, the 10-day SQT regimen resulted in a 100% eradication rate in all patients with CYP2C19 genotype RM and almost type of IL-1B (TC and TT) and IL1-RN genotypes ( 1/2 and other).
Conclusions: Treatment with 10-day sequential therapy is highly effective for H. pylori eradication regardless of the effects of clarithromycin resistance, dual clarithromycin and levofloxacin resistance, CYP2C19 genotype, IL-1B and IL1-RN genetic polymorphisms and can be used as effective first line therapy in Thailand.
Similar articles
-
High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.Asian Pac J Cancer Prev. 2015;16(10):4353-6. doi: 10.7314/apjcp.2015.16.10.4353. Asian Pac J Cancer Prev. 2015. PMID: 26028098 Clinical Trial.
-
Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.Helicobacter. 2013 Aug;18(4):270-3. doi: 10.1111/hel.12041. Epub 2013 Jan 29. Helicobacter. 2013. PMID: 23356886 Clinical Trial.
-
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.Clin Gastroenterol Hepatol. 2004 Jan;2(1):22-30. doi: 10.1016/s1542-3565(03)00288-x. Clin Gastroenterol Hepatol. 2004. PMID: 15017629 Clinical Trial.
-
Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.World J Gastroenterol. 2014 Jun 7;20(21):6400-11. doi: 10.3748/wjg.v20.i21.6400. World J Gastroenterol. 2014. PMID: 24914361 Free PMC article. Review.
-
Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori.J Gastroenterol Hepatol. 2009 Nov;24(11):1725-32. doi: 10.1111/j.1440-1746.2009.06047.x. J Gastroenterol Hepatol. 2009. PMID: 20136959 Free PMC article. Review.
Cited by
-
Scope and Limitations of Current Antibiotic Therapies against Helicobacter pylori: Reviewing Amoxicillin Gastroretentive Formulations.Pharmaceutics. 2022 Jun 24;14(7):1340. doi: 10.3390/pharmaceutics14071340. Pharmaceutics. 2022. PMID: 35890236 Free PMC article. Review.
-
Sequential versus Standard Triple Therapy for First-Line Helicobacter pylori Eradication: An Update.Antibiotics (Basel). 2024 Jan 30;13(2):136. doi: 10.3390/antibiotics13020136. Antibiotics (Basel). 2024. PMID: 38391522 Free PMC article. Review.
-
CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection.Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1243-1247. doi: 10.31557/APJCP.2019.20.4.1243. Asian Pac J Cancer Prev. 2019. PMID: 31030500 Free PMC article.
-
Low Re-infection Rate of Helicobacter pylori after Successful Eradication in Thailand: A 2 Years Study.Asian Pac J Cancer Prev. 2017 Mar 1;18(3):695-697. doi: 10.22034/APJCP.2017.18.3.695. Asian Pac J Cancer Prev. 2017. PMID: 28440977 Free PMC article.
-
First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines.Ann Gastroenterol. 2017;30(4):373-379. doi: 10.20524/aog.2017.0166. Epub 2017 Jun 1. Ann Gastroenterol. 2017. PMID: 28655973 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous